Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307362932> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W4307362932 abstract "<h3>Introduction</h3> The Christie is one of the first UK cancer centres to offer hyperthermic intraperitoneal chemotherapy(HIPEC) to patients with advanced epithelial ovarian cancer(AEOC). Though the OVHIPEC1-trial has demonstrated longer recurrence free and overall survival for patients undergoing interval cytoreductive surgery(CRS) with the addition of cisplatin based HIPEC compared to CRS alone, this treatment is not yet offered as NHS-funded treatment. We report early follow up data on safety and feasibility of CRS+HIPEC in ovarian cancer patients at the Christie, with an analysis of comparative perioperative costs. <h3>Methods</h3> Patients with high grade AEOC who achieved partial response to 3 or 4 cycles of neoadjuvant carboplatin-paclitaxel chemotherapy were selected for interval CRS+HIPEC. The procedure was performed by Gynaecological Surgical Oncologists in collaboration with Peritoneal Surgeons with extensive experience of CRS+HIPEC in colorectal and appendiceal malignancies. Closed HIPEC delivery technique was used. Cisplatin was perfused at 42°C for 90 minutes at 100 mg/m<sup>2</sup>. <h3>Results</h3> 9 patients have undergone CRS+HIPEC for AEOC at The Christie since October 2021. By the LBA submission deadline, this will be 10. We will report on median time to surgery from chemotherapy, pre- and postsurgical PCI score, mean length of stay and CCU stay, intra- and postoperative complications and 30 and 90 day mortality. Overall costs of the perioperative care of CRS+HIPEC will be compared to CRS alone in our setting. <h3>Conclusions</h3> Interval CRS+HIPEC is feasible, safe and cost effective for AEOC when performed collaboratively in a tertiary centre with a collocated peritoneal tumour service." @default.
- W4307362932 created "2022-10-31" @default.
- W4307362932 creator A5018716593 @default.
- W4307362932 creator A5019188914 @default.
- W4307362932 creator A5020983677 @default.
- W4307362932 creator A5032212968 @default.
- W4307362932 creator A5046170135 @default.
- W4307362932 creator A5089261636 @default.
- W4307362932 date "2022-10-01" @default.
- W4307362932 modified "2023-10-14" @default.
- W4307362932 title "2022-LBA-1618-ESGO A pilot study of interval cytoreductive surgery and HIPEC for advanced epithelial ovarian cancer in the UK" @default.
- W4307362932 doi "https://doi.org/10.1136/ijgc-2022-esgo.1025" @default.
- W4307362932 hasPublicationYear "2022" @default.
- W4307362932 type Work @default.
- W4307362932 citedByCount "0" @default.
- W4307362932 crossrefType "proceedings-article" @default.
- W4307362932 hasAuthorship W4307362932A5018716593 @default.
- W4307362932 hasAuthorship W4307362932A5019188914 @default.
- W4307362932 hasAuthorship W4307362932A5020983677 @default.
- W4307362932 hasAuthorship W4307362932A5032212968 @default.
- W4307362932 hasAuthorship W4307362932A5046170135 @default.
- W4307362932 hasAuthorship W4307362932A5089261636 @default.
- W4307362932 hasBestOaLocation W43073629321 @default.
- W4307362932 hasConcept C121608353 @default.
- W4307362932 hasConcept C126322002 @default.
- W4307362932 hasConcept C141071460 @default.
- W4307362932 hasConcept C2776694085 @default.
- W4307362932 hasConcept C2778239845 @default.
- W4307362932 hasConcept C2779458272 @default.
- W4307362932 hasConcept C2780427987 @default.
- W4307362932 hasConcept C2992773878 @default.
- W4307362932 hasConcept C2994223192 @default.
- W4307362932 hasConcept C31174226 @default.
- W4307362932 hasConcept C61434518 @default.
- W4307362932 hasConcept C71924100 @default.
- W4307362932 hasConceptScore W4307362932C121608353 @default.
- W4307362932 hasConceptScore W4307362932C126322002 @default.
- W4307362932 hasConceptScore W4307362932C141071460 @default.
- W4307362932 hasConceptScore W4307362932C2776694085 @default.
- W4307362932 hasConceptScore W4307362932C2778239845 @default.
- W4307362932 hasConceptScore W4307362932C2779458272 @default.
- W4307362932 hasConceptScore W4307362932C2780427987 @default.
- W4307362932 hasConceptScore W4307362932C2992773878 @default.
- W4307362932 hasConceptScore W4307362932C2994223192 @default.
- W4307362932 hasConceptScore W4307362932C31174226 @default.
- W4307362932 hasConceptScore W4307362932C61434518 @default.
- W4307362932 hasConceptScore W4307362932C71924100 @default.
- W4307362932 hasLocation W43073629321 @default.
- W4307362932 hasOpenAccess W4307362932 @default.
- W4307362932 hasPrimaryLocation W43073629321 @default.
- W4307362932 hasRelatedWork W1969454209 @default.
- W4307362932 hasRelatedWork W1979923959 @default.
- W4307362932 hasRelatedWork W2067366728 @default.
- W4307362932 hasRelatedWork W2091372359 @default.
- W4307362932 hasRelatedWork W2112625834 @default.
- W4307362932 hasRelatedWork W2164307258 @default.
- W4307362932 hasRelatedWork W2303672344 @default.
- W4307362932 hasRelatedWork W2400048705 @default.
- W4307362932 hasRelatedWork W2911542263 @default.
- W4307362932 hasRelatedWork W2953607890 @default.
- W4307362932 isParatext "false" @default.
- W4307362932 isRetracted "false" @default.
- W4307362932 workType "article" @default.